Bio-Rad Laboratories (BIO-B) Total Non-Current Liabilities (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Total Non-Current Liabilities data on file, last reported at $2.7 billion in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 2.46% year-over-year to $2.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 2.46% YoY) and the FY2025 annual result came in at $2.9 billion, up 11.7% from the prior year.
• Total Non-Current Liabilities declined to $2.7 billion in Q1 2026 per BIO-B's latest filing, from $2.9 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $4.0 billion in Q1 2022 and bottomed at $2.6 billion in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $3.3 billion (2023), against an average of $3.2 billion.
• Peak annual rise in Total Non-Current Liabilities reached 29.58% in 2022, while the deepest fall reached 22.85% in 2022.
• Tracing BIO-B's Total Non-Current Liabilities over 5 years: stood at $3.7 billion in 2022, then declined by 8.88% to $3.4 billion in 2023, then declined by 22.16% to $2.6 billion in 2024, then grew by 11.7% to $2.9 billion in 2025, then declined by 6.28% to $2.7 billion in 2026.
• Per Business Quant, the three latest BIO-B Total Non-Current Liabilities figures stand at $2.7 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.8 billion (Q3 2025).

Peer Comparison